ClickHouse Announces Native Postgres Service, Offering a Unified Data Stack for Real-Time and AI-Driven Applications
22.1.2026 17:00:00 CET | Business Wire | Press Release
ClickHouse, Inc., the company behind the world’s fastest real-time analytical database, announced a high-performance, enterprise-grade Postgres service natively integrated with ClickHouse, delivering a unified data stack for developers building modern, real-time and AI-driven applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260122173204/en/
ClickHouse Co-Founders (left to right): Yury Izrailevsky, Aaron Katz, Alexey Milovidov
The service is built in partnership with Ubicloud, Inc., an open-source cloud company delivering high-performance Postgres, led by a team with proven track record at Citus Data, Heroku, and Microsoft. This launch reinforces ClickHouse’s commitment to unifying transactional and analytical workloads on a single, scalable foundation.
This announcement also builds on ClickHouse’s acquisition of PeerDB Inc. in 2024, a Postgres company whose technology is helping power real-time data synchronization from Postgres to ClickHouse for hundreds of enterprise customers, validating the natural synergy between Postgres and ClickHouse.
A unified data stack for transactions and analytics
Modern, real-time AI applications require both transactional and analytical capabilities. ClickHouse is delivering a unified data stack that tightly integrates Postgres for transactions with ClickHouse for analytics. Developers get a high-performance Postgres service backed by NVMe storage and can synchronize transactional data from Postgres to ClickHouse in just a few clicks, unlocking up to 100x faster analytics. With a unified query layer, teams can build applications that seamlessly span transactions and analytics without the complexity of operating and managing separate systems.
“Postgres and ClickHouse have become foundational technologies for modern AI applications,” said Aaron Katz, CEO of ClickHouse. “With our native Postgres service, we’re unifying transactional and analytical workloads, so developers can build any type of application powered by AI on the best technical foundation. We’re excited to partner with Ubicloud and their world-class Postgres team to bring this offering to life.”
“Postgres and ClickHouse complement each other naturally and are key for AI applications. Together, we’re delivering an integrated stack that removes complexity for teams, with production-grade Postgres for transactions and ClickHouse for analytics working as one,” said Umur Cubukcu, Co-CEO, Co-Founder, Ubicloud. “We’re excited to join forces with ClickHouse at Ubicloud because this is how the open-source ecosystem wins: trusted teams building best-in-class products that work and grow together.”
Trusted by leading AI-driven companies
Thousands of companies, including GitLab, Instacart, Cloudflare, and Ramp, already rely on Postgres for transactional (OLTP) workloads and ClickHouse for analytical (OLAP) workloads to power mission-critical, real-time applications. With this launch, Postgres and ClickHouse move closer together, representing a major step toward a truly unified foundation for building AI applications.
Noah Pryor, the CTO of Beehiv, a large ClickHouse customer, shared excitement for this launch, “We’re excited to see ClickHouse entering the Postgres ecosystem. At Beehiv, we rely heavily on both Postgres and ClickHouse to power our mission-critical, customer-facing applications. We’ve invested significant effort in integrating these technologies, so a tighter, more native integration between them would materially simplify our architecture.”
Get started
Developers can sign up for the private preview of Postgres managed by ClickHouse today.
A detailed technical deep dive is available on the ClickHouse blog.
About ClickHouse
ClickHouse is a fast, open-source columnar database management system built for real-time data processing and analytics at scale. Engineered for high performance, ClickHouse Cloud delivers exceptional query speed and concurrency, making it ideal for applications that demand instant insight from massive volumes of data. As AI agents become increasingly embedded in software and are generating far more frequent and complex queries, ClickHouse brings a high-throughput, low-latency engine, purpose-built to meet this challenge. Trusted by leading companies like Sony, Tesla, Memorial Sloan Kettering, Lyft, and Instacart, ClickHouse helps teams unlock insights and drive smarter decisions with a scalable, efficient, and modern data platform. For more information, visit clickhouse.com.
About Ubicloud
Ubicloud is building the open-source AWS, delivering core cloud services across bare metal and public clouds. Founded by the team that built distributed PostgreSQL with Citus Data (acquired by Microsoft), Ubicloud’s flagship database offering, Ubicloud PostgreSQLprovides an enterprise-grade managed Postgres experience with industry-leading price-performance. Ubicloud services across AI, Compute, PostgreSQL, and Kubernetes power more than 1 million VMs every week, cutting cloud costs by up to 70%. Ubicloud is backed by Y Combinator and other prominent Silicon Valley investors. To learn more, follow Ubicloud on Twitter @ubicloudHQ or visit ubicloud.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260122173204/en/
Contacts
Press contact
Tanya Bragin
+1-818-321-1859
tanya@clickhouse.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom